← Back to Patent Explorer
US4192859A Expired / Lapsed US ⏱️ 0.0 years remaining

Contrast media containing liposomes as carriers

Assignee: Brookside Water Treatment Inc A Corp Of Mo
•
Filing: 1978-09-29
•
Granted: 1980-03-11
•
Expires: 1998-09-29
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract X-Ray contrast media are provided containing an X-ray contrast agent such as N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide, sodium diatrizoate, meglumine diatrizoate, sodium iodipamide, meglumine iodipamide and the like, and a liposome as a carrier therefor.

Inventors

  • 👤 George B. Mackaness
  • 👤 Joseph P. Hou

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 13:15
CPC Classifications
A; A61; A61K; A61K49/00; A61K49/04; A61K49/0433; A61K49/0447; A61K49/0461; A61K49/0466; Y; Y10; Y10S; Y10S424/00; Y10S424/90

Claims Analysis

Total Claims: 23
Claim 1
Independent Claim 49 words
An X-ray contrast medium comprising an X-ray contrast agent and a liposome as a carrier therefor, said liposome comprising a lecithin and a sterol, said X-ray contrast agent being present in an amount within the range of from about 20 to about 60% by weight of said contrast medium.
Claim 2
Dependent Claim 49 words
An X-ray contrast medium comprising an X-ray contrast agent and a liposome as a carrier therefor, said liposome comprising a lecithin and a sterol, said X-ray contrast agent being present in an amount within the range of from about 20 to about 60% by weight of said contrast medium.
Claim 3
Dependent Claim 101 words
The X-ray contrast medium as defined in claim 1 wherein said X-ray contrast agent is selected from the group consisting of N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide, metrizamide, diatrizoic acid, sodium diatrizoate, meglumine diatrizoate, acetrizoic acid and its soluble cationic salts, meglumine iocarmate, sodium iodipamide meglumine iodipamide, iodamide, iodohippuric acid and its soluble salts, diprotrizoic acid and its salts, iodomethamic acid, 3,5-diiodo-4-pyridone-N-acetic acid (iodopyracet), 3,5-diiodo-4-pyridone-N-acetic acid diethanolamine salt, iodo-2-pyridone-N-acetic acid and its amine salts, ioglycamic acid, iothalamic acid and its soluble salts, methanesulfonic acid, metrizoic acid, sodium metrizoate, sodium ipodate, ethiodized oil, iocetamic acid, iopanoic acid, tyropanoate sodium, iopydol, iophenoxic acid, and iophendylate, and mixtures thereof.
Claim 4
Dependent Claim 16 words
The X-ray contrast medium as defined in claim 2 wherein said X-ray contrast agent is N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide.
Claim 5
Dependent Claim 17 words
The X-ray contrast medium as defined in claim 2 wherein said X-ray contrast agent is sodium diatrizoate.
Claim 6
Dependent Claim 17 words
The X-ray contrast medium as defined in claim 2 wherein said X-ray contrast agent is meglumine diatrizoate.
Claim 7
Dependent Claim 17 words
The X-ray contrast medium as defined in claim 2 wherein said X-ray contrast agent is meglumine iodipamide.
Claim 8
Dependent Claim 17 words
The X-ray contrast medium as defined in claim 1 wherein said lecithin comprises egg or soy lecithin.
Claim 9
Dependent Claim 29 words
The X-ray contrast medium as defined in claim 7 wherein said sterol is selected from the group consisting of cholesterol, phytosterol, sitosterol, sitosterol pyroglutamate, 7-dehydrocholesterol, lanosterol and mixtures thereof.
Claim 10
Dependent Claim 14 words
The X-ray contrast medium as defined in claim 7 wherein said sterol is cholesterol.
Claim 11
Dependent Claim 16 words
The X-ray contrast medium as defined in claim 7 wherein said liposome further includes dicetyl phosphate.
Claim 12
Dependent Claim 15 words
The X-ray contrast medium as defined in claim 7 wherein said liposome further includes hexadecylamine.
Claim 13
Dependent Claim 36 words
A method for the X-ray visualization of body cavities and organs, which comprises administering to the body of the test object an effective contrast producing amount of an X-ray contrast medium as defined in claim 1.
Claim 14
Dependent Claim 12 words
The method as defined in claim 11 wherein the liver is visualized.
Claim 15
Dependent Claim 12 words
The method as defined in claim 11 wherein the spleen is visualized.
Claim 16
Dependent Claim 13 words
The method as defined in claim 11 wherein the gall bladder is visualized.
Claim 17
Dependent Claim 13 words
The method as defined in claim 11 wherein the spinal cord is visualized.
Claim 18
Dependent Claim 15 words
A method as defined in claim 11 wherein the X-ray contrast agent employed is N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide.
Claim 19
Dependent Claim 34 words
The method for the X-ray visualization of lymphatic channels, which comprises administering to the body of the test object an effective contrast producing amount of an X-ray contrast medium as defined in claim 1.
Claim 20
Dependent Claim 14 words
A method as defined in claim 14 wherein the X-ray contrast agent is N,N'-bis-[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide.
Claim 21
Dependent Claim 35 words
A method for the radiographic examination of the gastrointestinal tract, which comprises administering to the body of the test object an effective contrast producing amount of an X-ray contrast medium as defined in claim 1.
Claim 22
Dependent Claim 47 words
The X-ray contrast medium as defined in claim 1 where in said liposome carrier, said lecithin is present in an amount of from about 50 to about 85% by weight and said sterol is present in an amount of from about 10 to about 35% by weight.
Claim 23
Dependent Claim 33 words
The X-ray contrast medium as defined in claim 21 wherein said liposome carrier further includes dicetyl phosphate present in an amount of from 0 to about 30% by weight of said liposome carrier.

References Cited (Backward Citations)

US2613172A Cited
US3216900A Cited
FR3197M Cited
US3356575A Cited
US3957971A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1983-03-11 1983-09-10 1984-03-11 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1987-03-11 1987-09-10 1988-03-11 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1991-03-11 1991-09-10 1992-03-11 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag